Fresh From the Bench: Latest Precedential Patent Case
Contributed by Schwabe Williamson & Wyatt. Originally published on Patexia; republished here as part of the LexDana archive.
CASE OF THE WEEK
Copan Italia SPA v. Puritan Med. Prods. Co. LLC, Appeal No. 2022-1943 (Fed. Cir. May 14, 2024)
The Federal Circuit’s only precedential opinion concerning a patent case this week had nothing to do with patent law. Instead, it concerned whether a party could claim immunity under the COVID-19-related Pandemic Readiness and Emergency Preparedness Act (“PREP Act”).
The case focused on allegations of patent infringement for flocked swabs used for collecting biological specimens. The case was filed in 2018. When the COVID-19 pandemic hit in 2020, the case was stayed. Once the stay was lifted, Puritan asked the trial court to find it immune from suit under the PREP Act with regard to certain products that were made for the Air Force. The district court denied the motion to dismiss, finding too many factual disputes about whether and what products were needed for the Air Force contract. The district court did allow Puritan to include the PREP Act as an affirmative defense in an amended answer.
Editors:
Nika Aldrich, IP Litigation Group Leader, Schwabe, Williamson & Wyatt, P.C.
Jason A. Wrubleski, Shareholder
More insights
The Prosecution Data Most IP Attorneys Never Look At
Most prosecution strategy is set before anyone looks at who is actually examining the application. What is sitting there unused Every examiner has a history: allowance rate, average number of office actions, how often an interview changes the outcome. None…
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…